Skip to main
HSCS

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. is positioned for substantial growth as it enhances its AI-powered ECG diagnostic solutions, aiming to revolutionize cardiac screening in various healthcare settings. The company has raised its FY26 EPS estimate due to lower expenses, reflecting improved operational efficiency, while an increase in outstanding shares from 0.9 million to 3.2 million indicates robust equity financing to support its expansion. With a new price target of $9.20 based on a net present value analysis, HeartSciences demonstrates a strong potential for scalability, akin to a tolling model similar to app stores, further underpinning its positive financial outlook.

Bears say

HeartSciences Inc. is facing significant challenges that contribute to a negative outlook for its stock, primarily due to a lack of visibility regarding the timing of commercial revenues, leading to revised revenue estimates of $0.0 million for FY2026 and $0.4 million for FY2027. Additionally, operating expenses were reported at $2.1 million, only slightly below the estimated $2.2 million, which raises concerns about financial efficiency amid stagnant revenue projections. Further risks include potential issues with product safety and efficacy, regulatory approvals, commercialization efforts, reimbursement processes, and market competition, all of which indicate underlying financial vulnerabilities for the company.

HSCS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 1 analysts, HSCS has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.